Navin Fluorine International Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Sharp margin recovery, now at 24.3%: Operating EBITDA nearly doubled YoY, driven by higher HPP realizations, better capacity utilization at Dahej and Surat, and internal efficiencies. Management calls the 25% level sustainable but refuses to upgrade guidance beyond it.
• Project Nectar is live but will ramp slowly: Commissioned in November, first dispatches in December. Management is explicit: complex chemistry means a progressive, safety-first ramp, targeting only 40-45% of peak revenue in FY26.
• CDMO building toward a \$100 mn FY27 target: A scale-up order from a US major arrived this quarter, European direct dispatches began, and the cGMP4 Phase 1 build for the Fermion contract is on track. The BIOSECURE Act, though muted, is driving higher inquiries.
• Specialty Chemicals order book gives near-term visibility: The newly commissioned agro specialty plant has started commercial dispatches, and two new molecules are slated for introduction by Q1 FY26, securing the pipeline for the multipurpose plant.
• What to watch next quarter: The pace of Project Nectar’s ramp-up against the safety-first rhetoric, any specifics on the R32 expansion conversations with global majors, and whether the CDMO scale-up order converts into a long-term MSA.

Margin Recovery & Sustainability

• The 15-20-25 journey: Management framed the margin recovery as a deliberate execution of the Chairman’s stated priority to move margins from 15% to 20% to 25%. The jump to 24.3% this quarter was driven by ag chem recovery, higher HPP realizations, and capacity utilization, not a one-off event.
• Operating leverage is now structural: Roughly 5 percentage points of the margin improvement came from operating leverage, which management now considers sustainable given the order book’s line of sight.
• Gross margin was flattish QoQ: Despite HPP pricing and volumetric growth, gross margin did not expand meaningfully, with the flowdown to EBITDA coming from efficiencies secured within the businesses.
• Employee cost trajectory: The sustainable quarterly run rate for employee cost is INR70-75 crores, and the percentage of cost to sales on employee will start declining from Q4 onward.
• No upgrade beyond 25%: Management explicitly declined to raise margin guidance, stating the aim is to make the current level sustainable and grounded in the company’s foundation before considering any upgrade.

Ganatra: "Our aim here is to make this very sustainable, grounded in the -- in the kind of foundation of the company. And then as we move on and leverage comes in both with CDMO and HPP and speciality we will see what we will see, but we will not guide anything beyond the 25% at this stage."

Project Nectar: Commissioned, Now the Slow Ramp

• Live but deliberately paced: The plant was commissioned in November and first dispatches went out on 9th December. The asset was capitalized on that date, so depreciation and interest began flowing into the P&L immediately, with the full quarter effect visible in Q4.
• Chemistry dictates the speed: The process involves a high degree of chlorination at high temperatures and freezing. Management is explicit that it will not rush or take shortcuts, having learned from earlier organizational experiences with complex ramp-ups.
• Ramp-up trajectory: FY25 will see a gradual ramp, not full capacity. FY26 should reach roughly 40-45% of the peak annual revenue of ~INR515 crores. FY27 should approach par level.
• Dedicated capacity comes first: The initial focus is filling the capacity dedicated to the anchor partner, whose technology is being used. Management sees no demand or cost concerns for a successful ramp-up.
• Next year’s work: The coming year will meet customer requirements for both the current molecule and an additional molecule the customer has funded, while also running qualification batches to secure the FY27 order book.

Ganatra: "So because it's a complex chemistry, we are very, very clear that we want to ramp this project progressively, but in a safe and reliable manner. And this will ramp up, but it will take its time. We're not going to rush. We're not going to take any shortcuts."

CDMO: Building Toward the \$100 Million Target

• The FY27 target holds: Management continues to target \$100 million in CDMO revenue by FY27, with 30% of that coming from the European Fermion contract.
• Scale-up order from a US major: A process pre-process order delivered last quarter has now converted into a scale-up order from the same US customer, with supplies planned in Q4 FY25. This molecule may eventually translate into a long-term MSA and support growth beyond the \$100 million target.
• European dispatches begin: Direct dispatches to Europe commenced during the quarter as registration formalities reached an advanced stage. A separate order from a major European customer has also been received with a supply schedule for FY26.
• cGMP4 Phase 1 on track: The first phase of the INR160 crores investment, dedicated to the Fermion contract, is expected to commission by end of Q3 FY26. Management expects to ramp it very quickly once on stream, with peak revenue visible within the year, given the close partnership during construction.
• BIOSECURE tailwind is real but muted: The Act itself turned out less impactful than expected, but it raised questions with every large customer. The company is seeing higher inquiries as a result, and management remains very constructive on the CDMO business driven by these inquiries.
• FY26 outlook: Management expects strong growth from current levels, with active leadership attention on driving sales and relationships. Some molecules worked on in the past are being targeted to win orders back.

Ganatra: "I mean the -- you know Krishan you very well know that this is in this business, it takes time, right? So by the time you start doing work with the customer, it's not a 1-year relationship. It's a multiyear relationship. So there is enough opportunity to bond and grow together."

Specialty Chemicals: New Capacity, New Molecules

• Agro specialty plant live: The INR540 crores agro specialty plant at Dahej was successfully commissioned and commercial dispatches have started. This is a multipurpose plant with a revenue potential of INR270 crores.
• Two new molecules incoming: One new molecule will be introduced in Q4 FY25 and a second in Q1 FY26, both part of the multipurpose plant’s pipeline and tied to innovator customers in the agri space.
• Strong near-term visibility: Order visibility for Q4 FY25 and beyond is strong, particularly with the ongoing ramp-up at both Surat and Dahej facilities. The Surat capex of INR30 crores is already commissioned and working, with sales ramping gradually in FY26 and peaking in FY27.
• Export/domestic mix reversal: The mix flipped this quarter because supply is being made at the biggest global customer to their local supply chain partners. Going forward, the export versus domestic split will become more of a mismatch rather than following a predictable trend.
• Long-term ag chem view constructive: While near-term pricing pressure is expected, management sees long-term fundamentals for the ag chem sector as very constructive.

HPP & AHF: The License to Dream

• R32 expansion underway: An additional 4,500 metric tonnes of R32 capacity is progressing as planned and will be commissioned by February 2025. Management remains constructive on R32 demand globally and is engaged with global majors on evaluating further capacity enhancement.
• Strategic, not transactional: Conversations about further R32 expansion are ongoing, with management aiming for something more meaningful and strategic than a simple capacity add. Details on size, timeline, and capex were not disclosed, with a request for patience.
• AHF as a platform: The new INR450 crores AHF plant, on track for commissioning by early FY26, is described as a "license to dream" project: without AHF, there is no license to grow in fluorine chemistry. The goal is to keep increasing realization per kg of AHF.
• Captive consumption rising: With R32 capacity coming in, the company will become a significant captive consumer of its own AHF, creating a large opportunity as the project ramps up. External merchant sales are targeted at 6,000-7,000 metric tonnes.
• Supply security built in: The new HF plant is designed with flexibility to use fluorspar from any origin (Mexico, China, South Africa, Vietnam, Thailand), a deliberate move to secure supply beyond existing long-term contracts.
• High-purity AHF in development: Work on high-purity AHF technology is underway through collaboration with partners, but management declined to disclose details citing commercial sensitivities.

Ganatra: "The AHF capacity that has been put on. I mean, like I've always said, that's a license to dream project. It's a project, if you can't -- don't have AHF, there's no license to grow in this business, right?"

Inorganic Fluoride & Other Businesses

• Shift to high-purity niche: The inorganic fluoride business is pivoting toward high-purity materials like niche potassium fluoride and sodium fluoride rather than commodity KF. Price pressure exists but is less severe than in the normal KF market, and product mix plus operational efficiencies are helping contribution.
• Pharma applications emerging: Some inorganic salts are finding application in pharmaceuticals, opening a new demand avenue beyond traditional industrial uses.
• Sulfur costs factored in: Whatever sulfur price increases occurred are already reflected in the current numbers, with nothing further to factor in.

Guidance & Commitments

Key Metrics